July 31, 2024 7:17 PM

Benefit of Eisai and Biogen’s Alzheimer’s drug increases over time, studies suggest

The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer's meeting on Tuesday. In the companies' pivotal clinical trial, Leqembi reduced cognitive decline by 27% after 18 months - data that supported the drug's approval last year. The new study looked at how the drug performed in about 95% of trial patients who continued on the trea...